Pasar al contenido principal

POTENCIAL DE RECEPTORES DE ADENOSINA A2A/A3 O HETEROMEROS A2A/A3 MICROGLIALES COMO DIANAS DE NEUROPROTECCION EN ENFERMEDAD DE ALZHEIMER

RTI2018-094204-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

N-Methyl-D-aspartate (NMDA) and cannabinoid CB receptors form functional complexes in cells of the central nervous system, insights into the therapeutic potential of neuronal and microglial NMDA receptors

  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
  • Lillo, Alejandro
  • Lillo Jové, Jaume|||0000-0001-7712-0850
  • Rebassa, Joan Biel
  • Contestí, Joan S.
  • Saura Antolín, Carlos|||0000-0003-3692-5657
  • Franco, Rafael|||0000-0003-2549-4919
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
The cannabinoid CB receptor (CBR), which is a target to afford neuroprotection, and N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors, which are key in mediating excitatory neurotransmission, are expressed in both neurons and glia. As NMDA receptors are the target of current medication in Alzheimer's disease patients and with the aim of finding neuromodulators of their actions that could provide benefits in dementia, we hypothesized that cannabinoids could modulate NMDA function. Immunocytochemistry was used to analyze the colocalization between CB and NMDA receptors; bioluminescence resonance energy transfer was used to detect CB-NMDA receptor complexes. Calcium and cAMP determination, mitogen-activated protein kinase (MAPK) pathway activation, and label-free assays were performed to characterize signaling in homologous and heterologous systems. Proximity ligation assays were used to quantify CB-NMDA heteromer expression in mouse primary cultures and in the brain of APP transgenic mice, an Alzheimer's disease model expressing the Indiana and Swedish mutated version of the human amyloid precursor protein (APP). In a heterologous system, we identified CB-NMDA complexes with a particular heteromer print consisting of impairment by cannabinoids of NMDA receptor function. The print was detected in activated primary microglia treated with lipopolysaccharide and interferon-γ. CBR activation blunted NMDA receptor-mediated signaling in primary hippocampal neurons from APP mice. Furthermore, imaging studies showed that in brain slices and in primary cells (microglia or neurons) from APP mice, there was a marked overexpression of macromolecular CB-NMDA receptor complexes thus becoming a tool to modulate excessive glutamate input by cannabinoids. The results indicate a negative cross-talk in CB-NMDA complexes signaling. The expression of the CB-NMDA receptor heteromers increases in both microglia and neurons from the APP transgenic mice, compared with levels in samples from age-matched control mice. The online version contains supplementary material available at 10.1186/s13195-021-00920-6.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

  • Valenzuela Limiñana, Rita
  • Rodríguez Pérez, Ana Isabel
  • Costa Besada, María Alicia
  • Rivas Santisteban, Rafael
  • Garrido Gil, Pablo
  • López López, Andrea
  • Navarro, Gemma
  • Lanciego Pérez, José Luis
  • Franco Fernández, Rafael
  • Labandeira García, José Luis
ACE2 plays a pivotal role in the balance between the pro-oxidative pro-inflammatory and the anti-oxidative anti-inflammatory arms of the renin-angiotensin system. Furthermore, ACE2 is the entry receptor for SARS-CoV-2. Clarification of ACE2-related mechanisms is crucial for the understanding of COVID-19 and other oxidative stress and inflammation-related processes. In rat and monkey brain, we discovered that the intracellular ACE2 and its products Ang 1-7 and alamandine are highly concentrated in the mitochondria and bind to a new mitochondrial Mas-related receptor MrgE (MrgE) to produce nitric oxide. We found MrgE expressed in neurons and glia of rodents and primates in the substantia nigra and different brain regions. In the mitochondria, ACE2 and MrgE expressions decreased and NOX4 increased with aging. This new ACE2/MrgE/NO axis may play a major role in mitochondrial regulation of oxidative stress in neurons, and possibly other cells. Therefore, dysregulation of the mitochondrial ACE2/MrgE/NO axis may play a major role in neurodegenerative processes of dopaminergic neurons, where mitochondrial dysfunction and oxidative stress play a crucial role. Since ACE2 binds SARS-CoV-2 spike protein, the mitochondrial ACE2/MrgE/NO axis may also play a role in SARS-CoV-2 cellular effects.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors

  • Franco, Rafael
  • Morales, Paula
  • Navarro, Gemma
  • Jagerovic, Nadine
  • Reyes-Resina, Irene
The classical terms agonists and antagonists for G protein coupled receptors (GPCRs) have often become misleading. Even the biased agonism concept does not describe all the possibilities already demonstrated for GPCRs. The cannabinoid CB receptor (CBR) emerged as a promising target for a variety of diseases. Reasons for such huge potential are centered around the way drugs sit in the orthosteric and/or exosites of the receptor. On the one hand, a given drug in a specific CBR conformation leads to a signaling cascade that differs qualitatively and/or quantitatively from that triggered by another drug. On the other hand, a given drug may lead to different signaling outputs in two different tissues (or cell contexts) in which the conformation of the receptor is affected by allosteric effects derived from interactions with other proteins or with membrane lipids. This highlights the pharmacological complexity of this receptor and the need to further unravel the binding mode of CBR ligands in order to fine-tune signaling effects and therapeutic propositions., This work was partially supported by AARFD-17-503612 grant of the US Alzheimer’s Association and by grants SAF 2017-84117-R, RTI 2018-094204-B-I00, RTI 2018-095544-B-I00 and PID 2020-113430RB-I00 funded by Spanish MCIN/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by the “European Union” or by the “European Union Next Generation EU/PRTR”. PM is a postdoctoral fellow supported by the Juan de la Cierva Programme-MICIU (IJC 2019-042182-I). The research group of the University of Barcelona is considered of excellence (grup consolidat #2017 SGR 1497) by the Regional Catalonian Government, which does not provide any specific funding for reagents or for payment of services or Open Access fees, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adenosine A2A Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer's Disease

  • Franco, Rafael|||0000-0003-2549-4919
  • Rivas Santisteban, Rafael|||0000-0002-2078-6819
  • Casanovas, Mireia
  • Lillo, Alejandro
  • Saura Antolín, Carlos|||0000-0003-3692-5657
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
(1) Background. N-methyl d-aspartate (NMDA) ionotropic glutamate receptor (NMDAR), which is one of the main targets to combat Alzheimer's disease (AD), is expressed in both neurons and glial cells. The aim of this paper was to assess whether the adenosine A2A receptor (A2AR), which is a target in neurodegeneration, may affect NMDAR functionality. (2) Methods. Immuno-histo/cytochemical, biophysical, biochemical and signaling assays were performed in a heterologous cell expression system and in primary cultures of neurons and microglia (resting and activated) from control and the APPSw,Ind transgenic mice. (3) Results. On the one hand, NMDA and A2A receptors were able to physically interact forming complexes, mainly in microglia. Furthermore, the amount of complexes was markedly enhanced in activated microglia. On the other hand, the interaction resulted in a novel functional entity that displayed a cross-antagonism, that could be useful to prevent the exacerbation of NMDAR function by using A2AR antagonists. Interestingly, the amount of complexes was markedly higher in the hippocampal cells from the APPSw,Ind than from the control mice. In neurons, the number of complexes was lesser, probably due to NMDAR not interacting with the A2AR. However, the activation of the A2AR receptors resulted in higher NMDAR functionality in neurons, probably by indirect mechanisms. (4) Conclusions. A2AR antagonists such as istradefylline, which is already approved for Parkinson's disease (Nouriast® in Japan and Nourianz® in the US), have potential to afford neuroprotection in AD in a synergistic-like fashion. i.e., via both neurons and microglia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Single Point Mutation Blocks the Entrance of Ligands to the Cannabinoid CB Receptor via the Lipid Bilayer

  • Casajuana-Martin, Nil|||0000-0002-9007-274X
  • Navarro Brugal, Gemma|||0000-0003-4654-0873
  • Gonzalez, Angel|||0000-0002-2284-8307
  • Llinas del Torrent, Claudia|||0000-0002-6772-6856
  • Gómez-Autet, Marc|||0000-0002-6133-988X
  • Quintana García, Aleix|||0000-0003-4472-5129
  • Franco, Rafael|||0000-0003-2549-4919
  • Pardo Carrasco, Leonardo|||0000-0003-1778-7420
Molecular dynamic (MD) simulations have become a common tool to study the pathway of ligand entry to the orthosteric binding site of G protein-coupled receptors. Here, we have combined MD simulations and site-directed mutagenesis to study the binding process of the potent JWH-133 agonist to the cannabinoid CB receptor (CBR). In CBR, the N-terminus and extracellular loop 2 fold over the ligand binding pocket, blocking access to the binding cavity from the extracellular environment. We, thus, hypothesized that the binding pathway is a multistage process consisting of the hydrophobic ligand diffusing in the lipid bilayer to contact a lipid-facing vestibule, from which the ligand enters an allosteric site inside the transmembrane bundle through a tunnel formed between TMs 1 and 7 and finally moving from the allosteric to the orthosteric binding cavity. This pathway was experimentally validated by the Ala282 7.36 Phe mutation that blocks the entrance of the ligand, as JWH-133 was not able to decrease the forskolin-induced cAMP levels in cells expressing the mutant receptor. This proposed ligand entry pathway defines transient binding sites that are potential cavities for the design of synthetic modulators.